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The effects of an immunoaffinity-purified putative endogenous hypertensive factor (HF) on voltage-dependent calcium 
current in frog cardiac myocytes were assessed. In 9 out of 10 cells, HF reversibly increased the peak amplitude of the 
calcium current. HF increased peak calcium current density at -5 mV from a control level of 1.8 & 1.3 pA/pF (mean & SD) 
to 4.4 + 2.0 pA/pF. HF shifted the peak of the calcium current-voltage relationship in the hyperpolarizing direction. HF 
shifted the voltage dependence of the inactivation of the calcium current to more negative potentials with prepulses from 
40 to 0 mV, but the inactivation was not affected with prepulses more positive than 0 mV. Modulation of the voltage- 
dependent calcium current by HF may be the mechanism underlying its pressor effects. 
Ca*+ current; Ca2+ channel; Hypertension 
1. INTRODUCTION 
A factor has been isolated from the blood of 
spontaneously hypertensive rats which elevates 
blood pressure in normotensive animals and in- 
creases lanthanum-resistant calcium uptake by aor- 
tic rings [l]. Recent contractility studies have 
demonstrated that preincubation of aortic rings 
with this hypertensive factor (HF) had no effect on 
resting tension, but enhanced potassium- or nor- 
epinephrine-induced contractions [2]. This obser- 
vation suggests that depolarization is required for 
HF to have an effect on contractility. A hypothesis 
consistent with these data is that HF is acting on 
voltage-dependent calcium channels to enhance 
calcium influx. 
HF has been tentatively identified as a low 
molecular mass (700-800 Da) peptide [3,4]. This 
compound has now been further purified by mono- 
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clonal antibody affinity chromatography and we 
have examined its effects on the voltage-dependent 
calcium current (IQ). 
2. MATERIALS AND METHODS 
2.1. Electrophysiological recordings 
1~. was recorded from ventricular myocytes isolated by en- 
zymatic dissociation from the heart of adult Runa cutesbiuna 
[5,6]. These cells have been shown to contain only one type of 
Ca channel 171, the well-characterized dihydropyridine-sensitive 
(L-type) Ca channel. Suction electrodes were used for whole cell 
recordings. Interference from other ionic currents was minimiz- 
ed by including Cs in pipette and bath solutions to block K cur- 
rents and tetrodotoxin in the bath to block the fast Na current. 
Control Ringer solution consisted of (in mM): 103 NaCl, 20 
CsClz, 1.8 CaCl2, 1.8 MgCl2, 5 Na pyruvate, 5 glucose, 10 
Hepes, 0.0003 tetrodotoxin; pH 7.4 with NaOH. The recording 
pipette contained (in mM): 103 CsCl2, 4 MgClz, 5 EGTA, 5 
creatine phosphate, 10 Hepes, 3 ATP, 0.4 GTP; pH 7.1 with 
KOH. 
2.2. HFpurification 
HF was initially purified from rat erythrocytes by molecular 
sieve and ion exchange chromatography as in [3] and has the 
following composition: Asp/Asn (1.41), Ser (1.02), Glu/Gln 
(l.OO), and Gly (2.00). Further purification was achieved by af- 
finity chromatography using a mouse anti-HF antibody. Brief- 
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ly, BALB/c mice were immunized with a HF-ovalbumin con- 
jugate. Hybridomas producing monoclonal antibodies directed 
against HF were identified by means of an ELISA assay [8]. 
Subsequently, the antibody was produced by growing 
hybridoma cells as ascites tumors in BALB/c mice. The mono- 
clonal antibody present in the ascites fluid was purified by af- 
finity chromatography using protein A AvidGel F (BioProbe In- 
ternational) and an affinity column for purification of HF was 
prepared by covalently linking the anti-HF monoclonal anti- 
body to FMP AvidGel F. The peptide-containing fraction was 
dissolved in distilled water and recirculated through the column 
a miminum of three times. The column was washed with 5 bed 
volumes of distilled water, followed by 5 bed volumes of 0.01 M 
sodium acetate buffer, pH 4.5, containing 0.5 M NaCl, and 
again washed with distilled water. Material specifically bound to 
the column was eluted with 0.1 M acetic acid and the eluant 
lyophilized. Bioassay (enhancement of potassium-induced con- 
traction of rat aortic rings) of the lyophilized fractions indicated 
that activity was present only in the eluant obtained from the 
acetic acid wash. Following acid hydrolysis this fraction gave a 
positive ninhydrin reaction. A control, prepared by treatment of 
the column as described above except that the peptide- 
containing fraction was not circulated, indicated no biological 
activity nor the presence of ninhydrin-positive material in the 
acetic acid eluant. 
2.3. HF activity 
HF activity was determined by assessing the ability of the 
purified fraction to enhance potassium- and norepinephrine- 
induced contractions of rat thoracic aorta. We have used a 
quantity of HF sufficient to enhance these contractions by 40%. 
When the molar content of peptide was estimated by amino acid 
analysis [2], a similar enhancement of contraction was observed 
with a peptide concentration of 10e8 M. 
3. RESULTS 
Our first objective was to determine if HF af- 
fected the peak amplitude of Zca. Zca was activated 
by a voltage step from - 80 to - 5 mV for 200 ms 
every 8 s and the peak amplitude was measured as 
the difference between the peak inward current and 
the current at the end of the pulse. Addition of HF 
resulted in an enhancement of Zca (fig. 1A). HF in- 
creased the peak amplitude of Zca in 9 out of 10 
cells tested. The percentage increase of peak Zca 
varied from 55 to 750% (mean = 340%, n = 9). 
Under control conditions, the peak calcium current 
density averaged 1.8 + 1.3 pA/pF. This was in- 
creased to 4.4 + 2.0 pA/pF in the cells which 
responded to HF (n = 9). The increase in peak Zca 
(fig.lB), upon addition of HF, showed a rapid 
onset and was sustained throughout exposure to 
HF. Upon return to control Ringer solution, Zca 
rapidly came back to basal levels. 
A current-voltage relation for the peak Zca was 
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Fig. 1. Effect of HF on the voltage-dependent calcium current. 
Ic, was activated by 200 ms voltage steps from - 80 to - 5 mV 
every 8 s. Test solutions were applied by single cell superfusion. 
(A) Superimposed tracings of Zca before and during application 
of HF. (B) Peak calcium current, measured as the difference be- 
tween the maximum inward current and the current at the end 
of the pulse, plotted against ime. The cell was initially superfus- 
ed with control Ringer solution and then was exposed to HF- 
containing Ringer for the period indicated by the bar. Current- 
voltage, inactivation, and reactivation protocols for Zc. were 
run during the period indicated by the thin line. 
obtained in 3 cells with and without HF (fig.2). HF 
resulted in an increase in the peak amplitude of Zca 
at test potentials in the range of - 30 to 20 mV. HF 
also shifted the peak of the Z-V curve towards the 
hyperpolarizing direction. There was no change in 
the Zca recorded at 27 mV with HF. 
Fig.3 illustrates the voltage dependence of the in- 
activation of Zca with and without HF. Inactivation 
was assessed by measuring Zca at 0 mV following a 
400 ms prepulse to potentials from - 80 to 60 mV. 
This 400 ms prepulse was sufficiently long to en- 
sure that the calcium current was in steady-state in- 
activation. The inactivation curve exhibited a 
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Fig.2. Effect of HF on calcium current-voltage relationship. 
Peak Zca in the presence (0) and absence (0) of HF was 
measured following 200 ms voltage steps from - 80 mV and ex- 
pressed as a fraction of whole cell capacitance. Points are mean 
of three cells. Error bars represent standard deviations. 
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Fig.3. Effect of HF on the voltage dependence of calcium cur- 
rent inactivation. (0) Control, (0) HF. (A) Means and SD of 
calcium current inactivation measured between -80 and 
60 mV. n = 4. (B) Fit of data in A between - 80 and 0 mV. The 
points represent the means from A. The lines are the non-linear 
least-squares fits of the data to l/(1 + exp[(Z$,, -&2)/s]. For 
control EI/Z = - 25 and s = 5.6 and for HF El/2 = - 34 and 
s = 6.4. 
characteristic U-shape (fig3A) [7]. In the presence 
of HF, the inactivation of Ica was greater at more 
negative potentials. Above 0 mV, however, there 
was no difference in the degree of inactivation 
observed with or without HF. To quantify the ef- 
fects of HF on inactivation, the inactivation curve 
between - 80 and 0 mV was fitted to the relation 
l/[l + exp(& - E&S)] (fig.3B). HF shifted El/z 
from - 25.2 to - 37.8 and increased the slope fac- 
tor from 5.6 to 6.4. The reactivation, or time 
course of the recovery from steady-state inactiva- 
tion, of the calcium current, was measured at 0 mV 
[7]. HF did not affect reactivation of Ica (n = 3). 
4. DISCUSSION 
These data clearly demonstrate that HF 
modulates 1~~ by enhancing the amplitude of the 
current and by shifting the current-voltage and in- 
activation relationships in the hyperpolarizing 
direction. These effects of HF are similar to those 
seen in the presence of dihydropyridine calcium 
channel agonists [9-121 and less similar to those 
seen following phosphorylation of the calcium 
channel [5,7,13]. Inactivation of Ica is thought to 
consist of both voltage- and calcium-dependent 
components [141. Since HF does not alter inactiva- 
tion at positive potentials, it is likely that HF af- 
fects only the voltage-dependent component of in- 
activation. 
Recently, several peptides have been reported as 
modulators of calcium channel activity. Angioten- 
sin II increases Ica recorded from cultured rat car- 
diac myocytes [15]; however, it does not shift the 
current-voltage relationship and results in a slight 
depolarizing shift in the inactivation curve. Throm- 
bin also increases ka but does not result in a change 
in the voltage sensitivity of Ica [16]. Furthermore, 
the chemical composition of HF is not similar to 
these polypeptides [3]. An endogenous peptide 
purified from rat brain has recently been shown to 
affect calcium channels. This compound does 
enhance L-type 1~~ in heart and blocks it in 
neurons. The onset of its action is slower and its 
amino acid composition is different from HF [17]. 
The pressor and contractile properties of HF 
may be explained by its effects on the calcium cur- 
rent. Of course, to relate these effects on Ica to 
hypertension, it will be necessary to duplicate these 
experiments on smooth muscle. 
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